Taylor & Morgan Wealth Management’s Perspective Therapeutics CATX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$225K Buy
66,000
+37,000
+128% +$140K 0.11% 79
2026
Q1
$121K Sell
29,000
-68,000
-70% -$287K 0.07% 79
2025
Q4
$267K Buy
97,000
+6,000
+7% +$17.1K 0.15% 68
2025
Q3
$312K Sell
91,000
-3,000
-3% -$10.9K 0.19% 58
2025
Q2
$323K Buy
94,000
+4,000
+4% +$10.6K 0.22% 52
2025
Q1
$192K Buy
90,000
+34,000
+61% +$102K 0.14% 64
2024
Q4
$179K Buy
56,000
+26,000
+87% +$212K 0.13% 71
2024
Q3
$401K Buy
+30,000
New +$399K 0.27% 48
2024
Q2
Sell
-25,000
Closed -$298K 65
2024
Q1
$298K Sell
25,000
-37,500
-60% -$320K 0.22% 51
2023
Q4
$251K Buy
62,500
+5,000
+9% +$14.1K 0.2% 51
2023
Q3
$157K Sell
57,500
-2,058
-3% -$9.6K 0.14% 55
2023
Q2
$398K Sell
59,558
-16,426
-22% -$99.7K 0.33% 44
2023
Q1
$485K Sell
75,984
-1,051
-1% -$4.29K 0.42% 44
2022
Q4
$190K Hold
77,035
0.18% 62
2022
Q3
$177K Sell
77,035
-500
-0.6% -$1.71K 0.18% 60
2022
Q2
$240K Buy
77,535
+22,535
+41% +$68.8K 0.23% 59
2022
Q1
$200K Buy
55,000
+21,000
+62% +$76.6K 0.16% 60
2021
Q4
$132K Buy
+34,000
New +$181K 0.11% 64

Other funds holding CATX

Taylor & Morgan Wealth Management's CATX Position: Q2 2026 in Review

Taylor & Morgan Wealth Management increased its Perspective Therapeutics (CATX) stake by 128% in Q2 2026, buying an estimated $140K and bringing the position to 66,000 shares worth $225K. The position accounts for 0.11% of the portfolio, ranked #79.

Taylor & Morgan Wealth Management first reported a position in CATX in Q4 2021 and has held it in 18 quarters since. The position peaked at $485K in Q1 2023. 24 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Taylor & Morgan Wealth Management held 66,000 shares of Perspective Therapeutics worth $225K as of Q2 2026.
  • Taylor & Morgan Wealth Management bought 37,000 Perspective Therapeutics shares in Q2 2026, an estimated $140K.
  • Perspective Therapeutics made up 0.11% of Taylor & Morgan Wealth Management's portfolio in Q2 2026, its #79 holding.
  • Taylor & Morgan Wealth Management first reported a position in Perspective Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Taylor & Morgan Wealth Management's Perspective Therapeutics position peaked at $485K in Q1 2023.
  • 24 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Taylor & Morgan Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.